Robert L. Ferris, MD, PhD, editor-in-chief of Targeted Therapies in Oncology, discusses his monthly column in this episode of ...

A study shows talquetamab is a safe, effective bridge for high-risk patients, potentially improving outcomes and mitigating ...

A new study suggests the MAGIC Composite Response metric, which combines clinical and biomarker data, improves prediction of ...

Research reveals innovative methods for detecting minimal residual disease in ovarian cancer, enhancing prognosis and paving ...

New research reveals that GLP-1 receptor agonists significantly lower mortality risk in older cancer patients with type 2 ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Emerging treatments for low-grade serous ovarian cancer and platinum-resistant disease offer new hope, with promising data ...